Trump, Congress And The Future Of Value-Based Drug Contracting
Executive Summary
CMS-driven experiments in value-based purchasing may slow in the new US administration but commercial pressures to price drugs according to their value will not.
You may also be interested in...
Trump’s ACA Repeal: What’s In It For Biopharma?
Trump’s drive to repeal the Affordable Care Act offers opportunities for biopharma to eliminate the annual drug tax and roll back programs that could enable implementation of US government price controls on drugs without congressional action.
California’s Prop 61 Fails, But More Pricing Measures Could Be Ahead
A combination of effective biopharma industry opposition as well as a poorly designed policy proposal probably doomed the drug pricing measure.
US Outcomes-Based Contracts: Big Uptick In Interest, But Not Execution
The promise of outcomes-based contracts for biopharmaceuticals has yet to be realized in the US. Although precise numbers are hard to come by, payers and manufacturers agree the field is still nascent. However, they don’t seem to be giving up on the idea.